| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
149,990,000 |
| Market
Cap: |
137.98(M) |
| Last
Volume: |
394,168 |
Avg
Vol: |
182,850 |
| 52
Week Range: |
$0.9199 - $0.9199 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
96,155 |
6,836,925 |
6,836,925 |
6,836,925 |
| Total Buy Value |
$100,001 |
$7,110,902 |
$7,110,902 |
$7,110,902 |
| Total People Bought |
1 |
3 |
3 |
3 |
| Total Buy Transactions |
1 |
4 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bradsher Neal C |
Director |
– • • |
2022-03-24 |
4 |
B |
$1.42 |
$284,340 |
D/D |
200,000 |
34,465,485 |
3.92 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2022-03-23 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
34,265,485 |
2.17 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2022-03-23 |
4 |
B |
$1.37 |
$355,305 |
D/D |
260,106 |
34,265,485 |
3.92 |
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-12-31 |
4 |
D |
$2.45 |
$13,090 |
D/D |
(5,343) |
76,030 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,450 |
81,373 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2021-12-29 |
4 |
S |
$2.44 |
$92,438 |
D/D |
(37,695) |
0 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2021-12-29 |
4 |
OE |
$0.69 |
$6,400 |
D/D |
9,250 |
37,695 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2021-12-28 |
4 |
S |
$2.45 |
$1,228,891 |
D/D |
(501,588) |
28,445 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2021-12-28 |
4 |
OE |
$0.69 |
$718,704 |
D/D |
501,588 |
530,033 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-09-30 |
4 |
D |
$2.52 |
$13,464 |
D/D |
(5,343) |
65,923 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,450 |
71,266 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-06-30 |
4 |
D |
$2.85 |
$15,228 |
D/D |
(5,343) |
55,816 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-06-30 |
4 |
OE |
$2.85 |
$44,033 |
D/D |
15,450 |
61,159 |
|
- |
|
| Andrews Deborah J |
Director |
– • – |
2021-06-29 |
4 |
S |
$2.93 |
$56,086 |
D/D |
(19,142) |
15,578 |
|
- |
|
| Andrews Deborah J |
Director |
– • – |
2021-06-29 |
4 |
OE |
$2.20 |
$54,384 |
D/D |
24,720 |
34,720 |
|
- |
|
| Russell Angus C. |
Director |
– • – |
2021-06-29 |
4 |
S |
$2.97 |
$14,018 |
D/D |
(4,720) |
87,500 |
|
- |
|
| Russell Angus C. |
Director |
– • – |
2021-06-29 |
4 |
OE |
$2.20 |
$54,384 |
D/D |
24,720 |
92,220 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-06-28 |
4 |
AS |
$2.87 |
$1,291,500 |
D/D |
(450,000) |
45,709 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-06-28 |
4 |
OE |
$0.69 |
$207,570 |
D/D |
300,000 |
495,709 |
|
- |
|
| Bradsher Neal C |
Director |
– • • |
2021-06-25 |
4 |
OE |
$2.20 |
$54,384 |
D/D |
24,720 |
87,628 |
|
- |
|
| Kingsley Alfred D |
Director |
– • – |
2021-06-22 |
4 |
OE |
$2.20 |
$135,960 |
D/D |
61,800 |
5,470,245 |
|
- |
|
| Mulroy Michael H. |
Director |
– • – |
2021-06-18 |
4 |
OE |
$2.20 |
$54,384 |
D/D |
24,720 |
251,555 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-03-31 |
4 |
D |
$2.35 |
$12,556 |
D/D |
(5,343) |
195,709 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2021-03-31 |
4 |
OE |
$2.35 |
$36,308 |
D/D |
15,450 |
201,052 |
|
- |
|
| Hernandez Alexandra |
Sr Director Finance/Controller |
• – – |
2021-03-30 |
4 |
S |
$2.23 |
$13,380 |
D/D |
(6,000) |
0 |
|
- |
|
194 Records found
|
|
Page 2 of 8 |
|
|
